A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia.
Acquired pure red cell aplasia
Cyclosporine
Ferritin
Lymphocyte
Predictive models
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
03 Feb 2024
03 Feb 2024
Historique:
received:
05
10
2023
accepted:
19
01
2024
medline:
3
2
2024
pubmed:
3
2
2024
entrez:
2
2
2024
Statut:
aheadofprint
Résumé
Pure red cell aplasia (PRCA) is a rare bone marrow disorder characterized by a severe reduction or absence of erythroid precursor cells, without affecting granulocytes and megakaryocytes. Immunosuppressive therapies, particularly cyclosporine, have demonstrated efficacy as a primary treatment. This study aims to develop a predictive model for assessing the efficacy of cyclosporine in acquired PRCA (aPRCA). This retrospective study encompasses newly treated aPRCA patients at the General Hospital of Tianjin Medical University. Diagnosis criteria include severe anemia, and absolute reticulocyte count below 10 × 10
Identifiants
pubmed: 38308019
doi: 10.1007/s00277-024-05636-9
pii: 10.1007/s00277-024-05636-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Innovative Research Group Project of the National Natural Science Foundation of China
ID : 81170472
Organisme : Innovative Research Group Project of the National Natural Science Foundation of China
ID : 82270139
Organisme : Innovative Research Group Project of the National Natural Science Foundation of China
ID : 81970115
Organisme : Tianjin Research Program of Application Foundation and Advanced Technology of China
ID : 14JCYBJC27200
Organisme : Tianjin Research Program of Application Foundation and Advanced Technology of China
ID : 09JCYBJC11200
Organisme : Tianjin Municipal Science and Technology Committee
ID : TJWJ2023QN006
Organisme : Key Technologies Research and Development Program
ID : 18ZXDBSY00140
Organisme : The Zhaoyicheng Medical Science Foundation of Tianjin China
ID : ZYYFY2018026
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Nakazawa H, Sakai K, Ohta A et al (2022) Incidence of acquired pure red cell aplasia: a nationwide epidemiologic analysis with 2 registry databases in Japan. Blood Adv 6(24):6282–6290
doi: 10.1182/bloodadvances.2021006486
pubmed: 35522950
pmcid: 9806328
Krantz SB, Kao V (1967) Studies on red cell aplasia. I. Demonstration of a plasma inhibitor to heme synthesis and an antibody to erythroblast nuclei. Proc Natl Acad Sci USA 58(2):493–500
doi: 10.1073/pnas.58.2.493
pubmed: 4860752
pmcid: 335662
Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P (1996) Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 334(10):630–633
doi: 10.1056/NEJM199603073341004
pubmed: 8592526
Ganaie SS, Qiu J (2018) Recent advances in replication and infection of human parvovirus B19. Front Cell Infect Microbiol 8:166
doi: 10.3389/fcimb.2018.00166
pubmed: 29922597
pmcid: 5996831
Bernard C, Frih H, Pasquet F et al (2016) Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun Rev 15(1):82–92
doi: 10.1016/j.autrev.2015.09.005
pubmed: 26408958
Vlachaki E, Diamantidis MD, Klonizakis P, Haralambidou-Vranitsa S, Ioannidou-Papagiannaki E, Klonizakis I (2012) Pure red cell aplasia and lymphoproliferative disorders: an infrequent association. Sci World J 2012:475313
doi: 10.1100/2012/475313
Qiu ZY, Qin R, Tian GY, Wang Y, Zhang YQ (2019) Pathophysiologic mechanisms and management of large granular lymphocytic leukemia associated pure red cell aplasia. Onco Targets Ther 12:8229–8240
doi: 10.2147/OTT.S222378
pubmed: 31632073
pmcid: 6781944
Aung FM, Lichtiger B, Bassett R et al (2013) Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798–805
doi: 10.1111/bjh.12210
pubmed: 23330820
pmcid: 4078723
Azhar W, Zaidi F, Hannan A (2020) Isoniazid induced pure red blood cell aplasia. Cureus 12(2):e7112
pubmed: 32257659
pmcid: 7101238
Locatelli F, Del Vecchio L, Pozzoni P (2007) Pure red-cell aplasia “epidemic”–mystery completely revealed. Perit Dial Int 27(Suppl 2):S303–S307
doi: 10.1177/089686080702702s52
pubmed: 17556324
Macdougall IC, Casadevall N, Locatelli F et al (2015) Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant 30(3):451–460
doi: 10.1093/ndt/gfu297
pubmed: 25239637
Wang H, Niu H, Zhang T, Xing L, Shao Z, Fu R (2021) Low- and intermediate-risk myelodysplastic syndrome with pure red cell aplasia. Hematology 26(1):444–446
doi: 10.1080/16078454.2021.1929694
pubmed: 34153199
Balasubramanian SK, Sadaps M, Thota S et al (2018) Rational management approach to pure red cell aplasia. Haematologica 103(2):221–230
doi: 10.3324/haematol.2017.175810
pubmed: 29217782
pmcid: 5792266
Gurnari C, Maciejewski JP (2021) How I manage acquired pure red cell aplasia in adults. Blood 137(15):2001–2009
doi: 10.1182/blood.2021010898
pubmed: 33657207
pmcid: 8057257
Sawada K, Fujishima N, Hirokawa M (2008) Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 142(4):505–514
doi: 10.1111/j.1365-2141.2008.07216.x
pubmed: 18510682
pmcid: 2592349
Jiang H, Zhang H, Wang Y et al (2019) Sirolimus for the treatment of multi-resistant pure red cell aplasia. Br J Haematol 184(6):1055–1058
doi: 10.1111/bjh.15245
pubmed: 29741762
Long Z, Yu F, Du Y et al (2018) Successful treatment of refractory/relapsed acquired pure red cell aplasia with sirolimus. Ann Hematol 97(11):2047–2054
doi: 10.1007/s00277-018-3431-5
pubmed: 29982851
Fu R, Zhang T, Liu B et al (2018) The clinical characteristics and therapy response of patients with acquired pure red cell aplasia. Hematology 23(9):639–645
doi: 10.1080/10245332.2018.1470068
pubmed: 29754581
Lobbes H, Lega JC, Le Guenno G, Ruivard M, Mainbourg S (2023) Treatment strategy for acquired pure red cell aplasia: a systematic review and meta-analysis. Blood Adv 7(21):6451–6465
doi: 10.1182/bloodadvances.2023010587
pubmed: 37624775
pmcid: 10632686
Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association (2020) Chinese expert consensus on the diagnosis and treatment of acquired pure red cell aplasia. Zhonghua Xue Ye Xue Za Zhi 41(3):177–184
Hirokawa M, Sawada K, Fujishima N et al (2015) Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol 169(6):879–886
doi: 10.1111/bjh.13376
pubmed: 25807974
Kwong YL, Wong KF, Liang RH, Chu YC, Chan LC, Chan TK (1996) Pure red cell aplasia: clinical features and treatment results in 16 cases. Ann Hematol 72(3):137–140
doi: 10.1007/s002770050151
pubmed: 8766255
Huang Y, Chen M, Yang C, Ruan J, Wang S, Han B (2022) Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial. Leukemia 36(5):1351–1360
doi: 10.1038/s41375-022-01532-1
pubmed: 35256763
Liu X, Lu X, Chen L et al (2020) Immunosuppressive therapy for elderly-acquired pure red cell aplasia: cyclosporine A may be more effective. Ann Hematol 99(3):443–449
doi: 10.1007/s00277-020-03926-6
pubmed: 31970447
Lobbes H, Mahevas M, Alviset S et al (2021) Pure red cell aplasia in systemic lupus erythematosus, a nationwide retrospective cohort and review of the literature. Rheumatology (Oxford) 61(1):355–366
doi: 10.1093/rheumatology/keab363
pubmed: 33871586